GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arcturus Therapeutics Holdings Inc (NAS:ARCT) » Definitions » Asset Turnover

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Asset Turnover : 0.06 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Arcturus Therapeutics Holdings Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Arcturus Therapeutics Holdings's Revenue for the three months ended in Dec. 2023 was $25.1 Mil. Arcturus Therapeutics Holdings's Total Assets for the quarter that ended in Dec. 2023 was $443.5 Mil. Therefore, Arcturus Therapeutics Holdings's Asset Turnover for the quarter that ended in Dec. 2023 was 0.06.

Asset Turnover is linked to ROE % through Du Pont Formula. Arcturus Therapeutics Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was -16.77%. It is also linked to ROA % through Du Pont Formula. Arcturus Therapeutics Holdings's annualized ROA % for the quarter that ended in Dec. 2023 was -10.56%.


Arcturus Therapeutics Holdings Asset Turnover Historical Data

The historical data trend for Arcturus Therapeutics Holdings's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arcturus Therapeutics Holdings Asset Turnover Chart

Arcturus Therapeutics Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.33 0.03 0.03 0.49 0.36

Arcturus Therapeutics Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 0.17 0.02 0.10 0.06

Competitive Comparison of Arcturus Therapeutics Holdings's Asset Turnover

For the Biotechnology subindustry, Arcturus Therapeutics Holdings's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arcturus Therapeutics Holdings's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcturus Therapeutics Holdings's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Arcturus Therapeutics Holdings's Asset Turnover falls into.



Arcturus Therapeutics Holdings Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Arcturus Therapeutics Holdings's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=157.748/( (450.387+429.402)/ 2 )
=157.748/439.8945
=0.36

Arcturus Therapeutics Holdings's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=25.078/( (457.65+429.402)/ 2 )
=25.078/443.526
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Arcturus Therapeutics Holdings  (NAS:ARCT) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Arcturus Therapeutics Holdings's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-46.828/279.2875
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-46.828 / 100.312)*(100.312 / 443.526)*(443.526/ 279.2875)
=Net Margin %*Asset Turnover*Equity Multiplier
=-46.68 %*0.2262*1.5881
=ROA %*Equity Multiplier
=-10.56 %*1.5881
=-16.77 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Arcturus Therapeutics Holdings's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=-46.828/443.526
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-46.828 / 100.312)*(100.312 / 443.526)
=Net Margin %*Asset Turnover
=-46.68 %*0.2262
=-10.56 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Arcturus Therapeutics Holdings Asset Turnover Related Terms

Thank you for viewing the detailed overview of Arcturus Therapeutics Holdings's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Business Description

Traded in Other Exchanges
N/A
Address
10628 Science Center Drive, Suite 250, San Diego, CA, USA, 92121
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the segment of research and development of medical applications for nucleic acid-focused technology. The product pipeline of the company includes LUNAR-OTC, LUNAR-CF, and LUNAR-COV19.
Executives
Pad Chivukula officer: Chief Scientific Officer & COO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Keith C Kummerfeld officer: See Remarks 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Magda Marquet director ALTHEADX INC., 3550 DUNHILL STREET, SAN DIEGO CA 92121
John Markels director C/O SANGAMO THERAPEUTICS, INC., POINT RICHMOND TECH CTR, 501 CANAL BLVD., RICHMOND CA 94804
Joseph E Payne director, 10 percent owner, officer: President and CEO 10628 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO CA 92121
Jing L. Marantz director C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203
Ultragenyx Pharmaceutical Inc. director, 10 percent owner 60 LEVERONI COURT, NOVATO CA 94949
Lance Kurata officer: Chief Legal Officer 10628 SCIENCE CENTER DRIVE, SUITE 250, SAN DIEGO CA 92121
Andy Sassine officer: Chief Financial Officer 82 DEVONSHIRE STREET, BOSTON MA 02109
Steven George Hughes officer: Chief Development Officer 6275 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
James F Barlow director 2525 DUPONT DR, IRVINE CA 92612
Edward W Holmes director C/O TULARIK INC, TWO CORP DRIVE SOUTH, SAN FRANCISCO CA 8608257208
Peter C Farrell director RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949

Arcturus Therapeutics Holdings (Arcturus Therapeutics Holdings) Headlines

From GuruFocus

Arcturus Therapeutics to Attend the Following Investor Conferences

By Business Wire Business Wire 09-01-2022